Cardio-vascular
Refine search
Generics
The Russian drugmaker Binnopharm Group, which was founded by the local billionaire Vladimir Yevtushenkov, hopes to acquire Akrikhin, the local drugmaker, which is owned by the Polish-Dutch company Polpharma and which produces some important and best selling drugs in the Russian market. 14 April 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for German pharma major Bayer’s Kerendia (finerenone) in a new indication. 13 April 2026
Biotechnology
Dyno Therapeutics, a privately-held US genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Japan’s Astellas Pharma has exercised its option to license a novel adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle. 8 April 2026
Generics
The US Food and Drug Administration approved the first generics of UK pharma major AstraZeneca’s Farxiga (dapagliflozin) tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 8 April 2026
Pharmaceutical
US cardiorenal-focussed drugmaker Ardelyx announced the appointment of Rajani Dinavahi as Chief Medical Officer (CMO). 4 April 2026
Pharmaceutical
UK cost-effectiveness body the National Institute for Health and Care Excellence (NICE) has recommended Wegovy (semaglutide injection) 2.4mg alongside reduced-calorie diet and increased physical activity to reduce risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease who are either obese or overweight. 1 April 2026
Biotechnology
Emfret Analytics, a privately-held biotech developing platelet receptor–targeting antibodies for research, diagnostic and therapeutic applications, has signed a collaboration and license deal with fellow German firm Boehringer Ingelheim. 30 March 2026
Biotechnology
San Diego, USA-based late-stage biotech ADARx Pharmaceuticals announced the appointment of Ryan Fisk as chief financial officer and chief business officer. In this role, he will be responsible for leading finance, strategy, corporate development and investor relations for the company. 28 March 2026
Biotechnology
Braveheart Bio, a US biotech developing therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced the appointment of Emil deGoma as chief medical officer (CMO). 26 March 2026
Biotechnology
AI-powered disease detection and care coordination company Viz.ai has announced a partnership with RNAi therapeutics firm Alnylam Pharmaceuticals to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure. 25 March 2026
Biotechnology
UK-based Immutrin, a biotech developing next generation antibody therapy to reverse amyloidosis, has successfully raised £65 million ($87 million) in a Series A financing. 24 March 2026
Pharmaceutical
Days after announcing an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical, George Medicines has announced another deal relating to GMRx2. 16 March 2026
Pharmaceutical
UK-based cardiometabolic disease specialist George Medicines has entered into an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical. 11 March 2026
Pharmaceutical
Blog by Laurent Louette, director public affairs and country liaison at Vaccines Europe. 9 March 2026
Biotechnology
Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration. 6 March 2026
Pharmaceutical
Germany’s Bayer reported its financial results for the fourth quarter of 2025, along with the full year figures. 4 March 2026
Biotechnology
CRISPR gene editing company Intellia Therapeutics has announced that the US Food and Drug Administration (FDA) has removed the clinical hold on its Investigational New Drug application (IND) for the MAGNITUDE Phase III trial of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). 3 March 2026
Pharmaceutical
US pharma company Esperion Therapeutics has entered into an agreement to acquire Corstasis Therapeutics, a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease. 3 March 2026
Pharmaceutical
Atrium Therapeutics launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. 27 February 2026
Biotechnology
UK pharma major GSK has entered an agreement to acquire 35Pharma Inc, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics. 26 February 2026
Generics
The Russian drugmaker Binnopharm Group, which was founded by the local billionaire Vladimir Yevtushenkov, hopes to acquire Akrikhin, the local drugmaker, which is owned by the Polish-Dutch company Polpharma and which produces some important and best selling drugs in the Russian market. 14 April 2026
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for German pharma major Bayer’s Kerendia (finerenone) in a new indication. 13 April 2026
Biotechnology
Dyno Therapeutics, a privately-held US genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Japan’s Astellas Pharma has exercised its option to license a novel adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle. 8 April 2026
Generics
The US Food and Drug Administration approved the first generics of UK pharma major AstraZeneca’s Farxiga (dapagliflozin) tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 8 April 2026
Pharmaceutical
US cardiorenal-focussed drugmaker Ardelyx announced the appointment of Rajani Dinavahi as Chief Medical Officer (CMO). 4 April 2026
Pharmaceutical
UK cost-effectiveness body the National Institute for Health and Care Excellence (NICE) has recommended Wegovy (semaglutide injection) 2.4mg alongside reduced-calorie diet and increased physical activity to reduce risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease who are either obese or overweight. 1 April 2026
Biotechnology
Emfret Analytics, a privately-held biotech developing platelet receptor–targeting antibodies for research, diagnostic and therapeutic applications, has signed a collaboration and license deal with fellow German firm Boehringer Ingelheim. 30 March 2026
Biotechnology
San Diego, USA-based late-stage biotech ADARx Pharmaceuticals announced the appointment of Ryan Fisk as chief financial officer and chief business officer. In this role, he will be responsible for leading finance, strategy, corporate development and investor relations for the company. 28 March 2026
Biotechnology
Braveheart Bio, a US biotech developing therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced the appointment of Emil deGoma as chief medical officer (CMO). 26 March 2026
Biotechnology
AI-powered disease detection and care coordination company Viz.ai has announced a partnership with RNAi therapeutics firm Alnylam Pharmaceuticals to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure. 25 March 2026
Biotechnology
UK-based Immutrin, a biotech developing next generation antibody therapy to reverse amyloidosis, has successfully raised £65 million ($87 million) in a Series A financing. 24 March 2026
Pharmaceutical
Days after announcing an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical, George Medicines has announced another deal relating to GMRx2. 16 March 2026
Pharmaceutical
UK-based cardiometabolic disease specialist George Medicines has entered into an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical. 11 March 2026
Pharmaceutical
Blog by Laurent Louette, director public affairs and country liaison at Vaccines Europe. 9 March 2026
Biotechnology
Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration. 6 March 2026
Pharmaceutical
Germany’s Bayer reported its financial results for the fourth quarter of 2025, along with the full year figures. 4 March 2026
Biotechnology
CRISPR gene editing company Intellia Therapeutics has announced that the US Food and Drug Administration (FDA) has removed the clinical hold on its Investigational New Drug application (IND) for the MAGNITUDE Phase III trial of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). 3 March 2026
Pharmaceutical
US pharma company Esperion Therapeutics has entered into an agreement to acquire Corstasis Therapeutics, a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease. 3 March 2026
Pharmaceutical
Atrium Therapeutics launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. 27 February 2026
Biotechnology
UK pharma major GSK has entered an agreement to acquire 35Pharma Inc, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics. 26 February 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze